Orphan Drug Designation Granted to Peripheral T-Cell Lymphoma Treatment, CPI-614

Article

The FDA granted an orphan drug designation to Rafael Pharmaceuticals, Inc.’s CPI-613 for the treatment of peripheral T-Cell lymphoma (PTCL).

The US Food and Drug Administration (FDA) has granted an orphan drug designation to Rafael Pharmaceuticals, Inc.’s CPI-613 for the treatment of peripheral T-Cell lymphoma (PTCL).

CPI-613 is a novel lipoic acid analogue with an anticancer activity that inhibits multiple enzyme targets within the tricarboxylic acid cycle. Currently, 10 patients with relapsed or refractory T-Cell lymphoma are under investigation in a phase 1 trial with CPI-614 in combination with bendamustine. Of the 10 patients dosed, 7 were evaluated for efficacy.

“The orphan drug designation in this case provides hope to the poor-risk patient population and inspires us to continue our tireless effort to bring these patients a legitimate treatment option,” said Zanetta Lamar, MD, the principal investigator of the trial at Wake Forest Baptist, in a recent statement.

According to interim results presented at the American Society of Hematology (ASH) Annual Meeting in 2016 regarding CPI-613 in combination with bendamustine in 7 of the 10 dosed patients, an 86% objective response rate (43% complete response and 43% partial response) was observed.

"This study of CPI-613 in combination with bendamustine in patients with relapsed or refractory T-Cell Lymphoma showed a good safety profile and encouraging efficacy,” added Dr. Lamar.

Determination of the maximum tolerated dose (MTD) and safety profile of CPI-613 when used in combination with bendamustine to treat patients with relapsed or refractory T-Cell Lymphoma or classic Hodgkin Lymphoma is the primary objective of the current study.

Activation of a second clinical trial site for this study at the Abramson Cancer Center of the University of Pennsylvania was also recently announced by Rafael.

Recent Videos
Signs and Symptoms of Connective Tissue Disease
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
© 2024 MJH Life Sciences

All rights reserved.